The epidermal growth factor receptor (EGFR) is a transmembrane glycoprotein and receptor tyrosine kinase (TK) that is encoded by the *c-erbB-1* proto-oncogene ([Yarden and Sliwkowski, 2001](#bib53){ref-type="other"}). EGFR signalling is activated by ligands that induce homo- or heterodimerisation with other ErbB family members ([Yarden and Sliwkowski, 2001](#bib53){ref-type="other"}). Binding of a ligand to the extracellular domain of EGFR results in receptor dimerisation and autophosphorylation on tyrosine residues with the major phosphorylation site being tyrosine 1173 (Tyr-1173) ([Lombardo *et al*, 1995](#bib25){ref-type="other"}; [Chattopadhyay *et al*, 1999](#bib9){ref-type="other"}). EGFR activation triggers intracellular signalling that results in increased proliferation and a number of processes related to cell survival ([Yarden and Sliwkowski, 2001](#bib53){ref-type="other"}; [Buettner *et al*, 2002](#bib7){ref-type="other"}). EGFR expression is implicated in the pathogenesis of colorectal cancer ([Roberts *et al*, 2002](#bib42){ref-type="other"}) and a direct relationship between EGFR expression by colon cancer cells and their ability to produce hepatic metastasis has been shown in preclinical models ([Radinsky *et al*, 1995](#bib39){ref-type="other"}).

Evidence suggests that EGFR-activation status may be more important than receptor expression ([Piazzi *et al*, 2006](#bib38){ref-type="other"}). However, only limited data exist for phospho-EGFR in human colorectal cancers and highly variable expression frequencies were reported using an anti-Tyr 1068 antibody ([Cunningham *et al*, 2005](#bib15){ref-type="other"}; [Personeni *et al*, 2005](#bib37){ref-type="other"}). Till date, the prognostic effect of phospho-EGFR expression in human colon cancers has not been addressed. A polymorphism in the *EGFR* gene (R497K) was associated with a marked decrease in EGFR phosphorylation and was reported to be a favourable prognostic marker in stage II/III colorectal cancers ([Wang *et al*, 2007](#bib52){ref-type="other"}). In contrast to phospho-EGFR, EGFR expression in primary colon cancers has been shown to be an adverse prognostic marker in some ([Lee *et al*, 2002](#bib24){ref-type="other"}; [Resnick *et al*, 2004](#bib40){ref-type="other"}), but not other ([McKay *et al*, 2002](#bib30){ref-type="other"}; [Spano *et al*, 2005](#bib48){ref-type="other"}), studies and an evaluation of its prognostic effect using the FDA-approved antibody and methodology is lacking.

Recently, elongation of a microsatellite repeat at the 5′ untranslated region (UTR) was found in colon cancers with microsatellite instability (MSI), but not in microsatellite stable tumours ([Baranovskaya *et al*, 2009](#bib5){ref-type="other"}). Elongation of this repeat was shown to result in the downregulation of EGFR mRNA levels in human colon cancer cells and in human tumours with MSI. This report, however, did not examine EGFR protein expression levels in relation to MSI status. MSI results from defective DNA mismatch repair (MMR) and these tumours show distinct phenotypic features and are reported to have better stage-adjusted survival rates compared with tumours with intact MMR ([Sinicrope and Sargent, 2009](#bib47){ref-type="other"}).

In this report, we determined the prognostic effect of EGFR expression in relation to its activation status in primary stage II and III colon carcinomas from patients treated in 5-fluorouracil-based adjuvant therapy trials. We utilised antibodies against the major EGFR phosphorylation site Tyr-1173 and utilised the EGFR pharmDx kit. The association of EGFR with DNA MMR status, and phospho-EGFR or EGFR expression with cell proliferation and/or apoptosis were also studied.

Materials and methods
=====================

Patients and specimens
----------------------

Surgically resected, primary colon carcinomas were analysed from patients who participated in randomized 5-fluorouracil-based adjuvant chemotherapy trials conducted by the North Central Cancer Treatment Group (NCCTG: 91-46-53, 79-46-04, 89-46-51). Details of these studies have been previously reported ([Allegra *et al*, 2002](#bib3){ref-type="other"}; [O\'Connell *et al*, 2006](#bib33){ref-type="other"}). Paraffin-embedded tumour blocks were available from a non-random patient subset of the overall study populations. Phospho-EGFR was analysed in 388 patients with TNM stage II and III colon carcinomas. EGFR was studied in 303 stage II and III cases from a single adjuvant trial (91-46-53). Tumour histological grade was categorized as: grade 1, well differentiated; grade 2, moderately differentiated; grade 3, poorly differentiated; and grade 4, undifferentiated ([Compton *et al*, 2000](#bib12){ref-type="other"}).

All patients were censored at 5 years after randomisation for disease-free survival (DFS) and were followed for a median of 8 years for overall survival (OS).

Tissue microarrays (TMA)
------------------------

Tissue microarrays had been constructed from paraffin tumour blocks (Beecher Instruments, Silver Spring, MD, USA). Each patient had three tumour cores and two normal cores consisting of normal liver, tonsil or placenta that were used as Immunohistochemistry (IHC) controls and navigation markers ([Jourdan *et al*, 2003](#bib21){ref-type="other"}). Tissue sections (4--6 *μ*m) were cut from TMA blocks for IHC.

Immunohistochemistry
--------------------

Slides were deparaffinized, endogenous peroxidase activity was blocked and staining was carried out using a DAKO Cytomation Autostainer (DAKO, Carpinteria, CA, USA). For phospho-EGFR, heat-induced epitope retrieval was carried out in EDTA using a steamer (30 min, 98--100°C). Slides were placed into a wash buffer (Tris-buffered saline solution containing 0.05% Tween 20, pH 7.6 (DAKO)) and then a serum-free protein block was applied (DAKO) for 10 min. After rinsing in wash buffer, slides were incubated overnight at 4°C with the anti-phospho-EGFR (Tyr-1173) mouse monoclonal antibody (DAKO), diluted 1 : 100. After rinsing, a secondary antibody system (advance HRP (DAKO)) was applied for 15 min. For EGFR, non-specific antibody binding was inhibited using a protein block BACKGROUND*SNIPER* (Biocare Medical, Walnut Creek, CA, USA). Slides were stained for EGFR using the Dako pharmDx kit (DAKO) as per the manufacturer\'s instructions. Colour was developed using diaminobenzidine followed by counterstaining with hematoxylin. For both antibodies, a breast carcinoma was used as a positive control and a negative control omitted the primary antibody but included all other steps.

For the analysis of Ki-67 and caspase-3, antigen retrieval was carried out using a heat-inactivated epitope retrieval system, EDTA*DECLOAKER* (Biocare). Double staining for caspase-3 and Ki-67 was carried out by incubating sections in a prediluted monoclonal and polyclonal antibody double stain cocktail, Ki-67(M)+caspase-3(R) (Biocare) for 60 min. Slides were then incubated with MACH 2 (HRP(ms)+ALP(rb)) secondary antibody cocktail (Biocare) for 30 min. Next, sections were incubated in Cardassian DAB (HRP) to visualise Ki-67 and in Vulcan Fast Red (ALP) to visualise caspase-3 (both reagents from Biocare). Slides were counterstained in hematoxylin.

IHC scoring
-----------

Phospho-EGFR was scored as having either weak/moderate (1+ and 2+) or absent staining intensity in the tumour cytoplasm. Membranous EGFR staining was scored as per the manufacturer\'s instructions (Guidelines for Interpreting EGFR pharmDx, DAKO), and intensity was categorised as follows: 0 (no staining), 1+ (incomplete circumferential staining), 2+ (complete circumferential staining), and 3+ (complete strong circumferential staining). We regarded tumours with \>5% of stained tumour cells to be positive for either marker. Staining results were found to be very similar among cores and in the event of a difference, we selected the core with higher staining intensity provided that that tumour--to--background signal was optimal. Staining criteria were reviewed in a random subset by two pathologists (RLR, TCS) before scoring all cases. All specimens were then analysed by a pathologist (RLR) without the knowledge of clinical information.

Ki-67 and caspase-3 staining were scored using computerised TMA images of individual tissue core images on a given slide (Slide Scanner; Bacus Laboratories, Lombard, IL, USA), as previously described ([Sinicrope *et al*, 2007](#bib44){ref-type="other"}). The number of Ki-67- and caspase-3-positive cells was determined, and mean and median values were calculated. The caspase-3 : Ki-67 ratio was determined by dividing number of caspase-3 events by number of positive Ki-67 cells.

DNA MMR status
--------------

Defective DNA MMR was defined as absent expression of an MMR protein by IHC and instability at the BAT 26 locus, as previously described ([Thibodeau *et al*, 1998](#bib50){ref-type="other"}; [Parc *et al*, 2000](#bib36){ref-type="other"}; [Garrity *et al*, 2004](#bib16){ref-type="other"}) for adjuvant study 91-46-53. For the other studies, MSI was analysed as previously described ([Thibodeau *et al*, 1998](#bib50){ref-type="other"}; [Halling *et al*, 1999](#bib19){ref-type="other"}) and tumours with high frequency instability (MSI-H, ⩾30% of the loci demonstrating MSI) ([Boland *et al*, 1998](#bib6){ref-type="other"}; [Halling *et al*, 1999](#bib19){ref-type="other"}) were regarded as showing defective MMR, whereas the others were categorized as showing intact MMR.

Statistical analysis
--------------------

Chi-square tests were used to test for an association between categorical variables and the Wilcoxon rank-sum test was used to test for an association between a dichotomized variable and a continuous variable. OS (censored at 8 years) was calculated as the number of years from random assignment to the date of death or last contact. DFS (censored at 5 years) was calculated as the number of years from random assignment to the date of disease recurrence or death. The distributions of OS and DFS were estimated using Kaplan--Meier methodology. Univariate and multivariate Cox\'s proportional hazards models ([Cox, 1972](#bib14){ref-type="other"}) were used to explore the association of clinical and laboratory parameters with OS and DFS. Graphical methods were used to examine whether the underlying model assumptions were satisfied (e.g., proportional hazards) ([Grambsch and Terry, 1994](#bib17){ref-type="other"}). Statistical tests were two sided, with *P*⩽0.05 considered significant. *P*-values were not adjusted for multiple comparisons. Statistical analyses were carried out using SAS software (SAS Institute, Cary, NC, USA).

Results
=======

Study population
----------------

Patient demographic data and clinicopathological features of the colon carcinomas examined in this study are shown in [Table 1](#tbl1){ref-type="table"}. Patients whose tumours were analysed for phospho-EGFR had a median age of 64 years (mean 62.5, range 26--85). For EGPR, median age was 64 years (mean 62, rage 30--83).

Phospho-EGFR, EGFR expression, and clinicopathological features
---------------------------------------------------------------

Phospho-EGFR (Tyr-1173) expression was detected in 157 of 388 (40%) colon cancers ([Table 1](#tbl1){ref-type="table"}). Staining intensity was weak/moderate (1+ and 2+) and localised to the tumour cytoplasm ([Figure 1A](#fig1){ref-type="fig"}). EGFR expression was analysed using the EGFR pharmDx kit that was approved by the United States Food and Drug Administration to assess patient eligibility for treatment with anti-EGFR antibodies. We found that 214 of 361 (59%) colon carcinomas examined showed EGFR plasma membrane staining (1--3+). Absent/weak/moderate EGFR intensity (0, 1+, and 2+) was detected in 301 (83%) tumours and complete strong circumferential staining (3+) was found in 60 (17%) ([Table 1](#tbl1){ref-type="table"}, [Figure 1B](#fig1){ref-type="fig"}).

Phospho-EGFR expression did not correlate with the clinicopathological variables ([Table 2](#tbl2){ref-type="table"}). Colon cancers with strong EGFR (3+) *vs* other intensities (0--2+) were significantly more likely to be stage III (87 *vs* 73%; *P*=0.03) ([Table 2](#tbl2){ref-type="table"}). EGFR intensity was unrelated to patient age, gender, or tumour site ([Table 2](#tbl2){ref-type="table"}). We also compared mean and median EGFR values with the clinicopathological variables. Poor/undifferentiated tumours had significantly higher EGFR intensity compared with tumours with well/moderate histological grade (*P*=0.007) (data not shown). Expression of EGFR and phospho-EGFR were not correlated in a patient subset wherein both proteins were analysed (*n*=190; *P*=0.45). However, 32 of the 190 cases expressed phospho-EGFR but were negative for EGFR. When these 32 cases were excluded, EGFR expression was significantly correlated with phospho-EGFR (*P*\<0.0001).

We found that 33 of 360 (9%) colon cancers showed defective DNA MMR and 327 (91%) showed intact MMR ([Table 1](#tbl1){ref-type="table"}). Tumours with defective MMR were significantly more likely to show proximal location, poor/undifferentiated histology, and to be from older aged patients compared to cases with intact MMR (data not shown), as previously reported ([Lothe *et al*, 1993](#bib26){ref-type="other"}; [Thibodeau *et al*, 1993](#bib49){ref-type="other"}, [1998](#bib50){ref-type="other"}; [Halling *et al*, 1999](#bib19){ref-type="other"}; [Gryfe *et al*, 2000](#bib18){ref-type="other"}; [Sinicrope *et al*, 2006a](#bib45){ref-type="other"}, [2006b](#bib46){ref-type="other"}). Recently, elongation of a microsatellite repeat at the 5′ UTR was found in colon cancers with defective MMR, but not in those with intact MMR ([Baranovskaya *et al*, 2009](#bib5){ref-type="other"}), and elongation of this repeat was associated with downregulation of EGFR mRNA levels. Accordingly, we compared EGFR expression with MMR status in our study population. As a dichotomised variable, EGFR intensity was unrelated to MMR status ([Table 2](#tbl2){ref-type="table"}). Mean and median EGFR intensity were, however, increased in tumours with defective *vs* intact MMR, but did not reach statistical significance (*P*=0.065).

Association of phospho-EGFR and EGFR with cell proliferation and apoptosis
--------------------------------------------------------------------------

Tumour growth rates are governed by the counterbalancing processes of cell proliferation and apoptosis, as measured here by Ki-67 and caspase-3 expression in a patient subset (*n*=190) ([Figure 1C](#fig1){ref-type="fig"}). Weak/moderate (1+ and 2+) staining intensity (*vs* absent) for phospho-EGFR was associated with a higher mean and median number of Ki-67-positive tumour cells (*P*=0.015) ([Table 2](#tbl2){ref-type="table"}). Furthermore, tumours with strong (3+) EGFR staining intensity (*vs* other) had a higher mean and median number of Ki-67-positive tumour cells (*n*=361; *P*=0.0002) ([Table 2](#tbl2){ref-type="table"}). Tumours with poor/undifferentiated histology had a higher mean and median number of Ki-67-positive tumour cells as compared with tumours with well/moderate histologic grade (*P*=0.0004) (data not shown). Phospho-EGFR staining and strong EGFR staining intensity were not significantly associated with caspase-3 expression nor with the caspase-3/ki-67 ratio ([Table 2](#tbl2){ref-type="table"}).

Association of phospho-EGFR and EGFR with patient survival
----------------------------------------------------------

The median duration of follow-up for patients who remain alive was 8 years. We analysed phospho-EGFR and EGFR staining intensity as continuous variables. In a univariate analysis, patient tumours expressing phospho-EGFR had similar DFS and OS survival rates ([Figure 2](#fig2){ref-type="fig"}) as did tumours lacking phospho-EGFR ([Table 1](#tbl1){ref-type="table"}). Increasing EGFR intensity was associated with significantly shorter 5-year DFS (hazard ratio (HR) (95% CI): 1.21 (1.03, 1.41), *P*=0.019) and OS (HR: 1.19 (1.02, 1.39), *P*=0.028) rates ([Table 1](#tbl1){ref-type="table"}; [Figure 3A and B](#fig3){ref-type="fig"}). We also analysed EGFR as a dichotomised variable and compared tumours with absent/weak/moderate EGFR intensity (0, 1+, and 2+) *vs* strong (3+) staining ([Figure 3C and D](#fig3){ref-type="fig"}). We found that patients with tumours that showed strong staining had significantly reduced 5-year DFS (HR (95% CI): 1.65 (1.07, 2.53), *P*=0.022) and OS (HR: 1.55 (1.00, 2.39), *P*=0.47) rates ([Table 1](#tbl1){ref-type="table"}). We then determined whether tumours expressing both EGFR and phospho-EGFR (*n*=158) had a poorer prognosis compared with those with EGFR alone. However, no differences in survival were found indicating that activation of EGFR Tyr-1173 does not further affect prognosis in EGFR-expressing tumours. Neither Ki-67 nor caspase-3 staining was prognostic. Lower tumour stage (II *vs* III) and lesser number of metastatic lymph nodes were significantly associated with more favourable DFS and OS rates ([Table 1](#tbl1){ref-type="table"}). Furthermore, tumours with better differentiation showed more favourable OS rates ([Table 1](#tbl1){ref-type="table"}). MMR status in tumours was not a significant prognostic variable (*n*=360) ([Table 1](#tbl1){ref-type="table"}).

In a multivariate analysis, EGFR intensity was analysed as a continuous variable and was independently associated with shorter DFS (HR: 1.18 (1.01, 1.38), *P*=0.042) ([Table 3](#tbl3){ref-type="table"}). EGFR intensity was also borderline significance for OS (HR: 1.15 (0.98, 1.34), *P*=0.086) in a model that included age, tumour stage, histological grade, and MMR status ([Table 3](#tbl3){ref-type="table"}). The analysis of EGFR dichotomised as strong (3+) intensity *vs* other intensities showed similar results for DFS (data not shown). Within this model, substituting the number of metastatic lymph nodes for tumour stage yielded similar results for EGFR intensity. Given the lack of association of phospho-EGFR and clinical outcome by univariate analysis, it was not studied multivariately. However, we examined the prognosis of the subset of tumours expressing both EGFR and phospho-EGFR compared with EGFR alone. No differences were found between these tumour subsets, thus suggesting that the EGFR activation status does not confer additional prognostic information.

Discussion
==========

Although EGFR expression has been studied in colorectal cancers ([Lee *et al*, 2002](#bib24){ref-type="other"}; [McKay *et al*, 2002](#bib30){ref-type="other"}; [Spano *et al*, 2005](#bib48){ref-type="other"}), only limited and inconsistent data are available concerning the EGFR activation status in this malignancy. Furthermore, no studies have addressed the prognostic effect of phospho-EGFR in colon cancer patients. Accordingly, we analysed phospho-EGFR and EGFR expression in a large series of stage II and III colon cancers from completed 5-fluorouracil-based adjuvant therapy trials ([O\'Connell *et al*, 2006](#bib33){ref-type="other"}). Phospho-EGFR expression was detected in 157 of 388 (40%) colon cancers using an antibody that recognises the major EGFR autophosphorylation site at Tyr-1173. Tyr-1173 serves as a major binding site for Shc, an adaptor protein involved in signalling between EGFR and Ras ([Okabayashi *et al*, 1994](#bib34){ref-type="other"}) and also as a binding site for phosphatases ([Agazie and Hayman, 2003](#bib1){ref-type="other"}), that have an important role in modulating EGFR activity. Although the expression of phospho-EGFR was not associated with clinicopathological variables, both phospho-EGFR and EGFR were significantly associated with higher rates of cell proliferation, but not apoptosis, consistent with unopposed cell proliferation. The association of EGFR activation and expression with cell proliferation likely reflects downstream signalling, including Ras and ERK activation. ERK translocates to the nucleus and phosphorylates transcription factors that regulate genes controlling cell proliferation, including cyclin D1 ([Cesana *et al*, 2006](#bib8){ref-type="other"}) that is overexpressed in 30--50% of colorectal carcinomas and is associated with a poor prognosis ([Arber *et al*, 1996](#bib4){ref-type="other"}; [McKay *et al*, 2000](#bib29){ref-type="other"}). Phospho-EGFR was not prognostic in our study which is concordant with the data obtained from non-small cell lung cancer and breast cancer patients, wherein no associations with survival were found ([Cortas *et al*, 2007](#bib13){ref-type="other"}; [Nieto *et al*, 2007](#bib32){ref-type="other"}). Although we studied a major EGFR phosphorylation site, it is possible that activation at other EGFR autophosphorylation sites may confer prognostic information.

We detected membranous EGFR expression using the EGFR pharmDx kit in 214 (59%) colon carcinomas. Potential mechanisms for EGFR expression include its transcriptional upregulation, decreased degradation, or gene amplification ([Komuta *et al*, 1995](#bib22){ref-type="other"}; [Shia *et al*, 2005](#bib43){ref-type="other"}). We found that strong EGFR intensity was significantly associated with higher tumour stage (III *vs* II) as compared with weaker EGFR intensity. EGFR protein expression was unrelated to tumour MMR status. This finding does not support a recent study that found elongation of a dinucleotide repeat in 55% of colon cancers with defective MMR, that was associated with significantly reduced EGFR mRNA levels ([Baranovskaya *et al*, 2009](#bib5){ref-type="other"}). EGFR intensity as a continuous EGFR variable was significantly associated with shorter DFS and OS rates in a univariate analysis. EGFR was also a significant prognostic variable for DFS and OS when dichotomized as strong *vs* other intensity. In a recent study, strong (3+) EGFR staining was predictive of a high level of EGFR gene amplification ([Hemmings *et al*, 2009](#bib20){ref-type="other"}), although conflicting reports exist ([Milano *et al*, 2008](#bib31){ref-type="other"}). In a multivariate analysis, we found that EGFR intensity was independently associated with shorter DFS and was of borderline statistical significance for OS. Some ([Lee *et al*, 2002](#bib24){ref-type="other"}; [Resnick *et al*, 2004](#bib40){ref-type="other"}), but not other studies ([McKay *et al*, 2002](#bib30){ref-type="other"}; [Spano *et al*, 2005](#bib48){ref-type="other"}), have shown an adverse prognostic effect for EGFR expression in colorectal cancer patients. It is important to note that we used the U.S. FDA-approved EGFR pharmDx kit with its specific guidelines for EGFR scoring. Tumour stage, lymph node metastases, and histological grade were prognostic variables in our patient population. The lack of a survival advantage for tumours with defective MMR status may be related to the sample size and/or the observation that colon cancers with defective MMR do not respond to adjuvant 5-fluorouracil, whereas those with intact MMR receive a survival benefit from 5-fluorouracil treatment ([Ribic *et al*, 2003](#bib41){ref-type="other"}).

Our findings are similar to a study in high-risk breast cancer patients where EGFR, but not phospho-EGFR, was an adverse prognostic factor ([Nieto *et al*, 2007](#bib32){ref-type="other"}). This study utilised the phospho-EGFR Tyr 1086 antibody in breast cancers ([Nieto *et al*, 2007](#bib32){ref-type="other"}) and reported a lack of association with EGFR, as was also found in our colorectal cancers and has been reported in other epithelial malignancies ([Cunningham *et al*, 2005](#bib15){ref-type="other"}; [Kong *et al*, 2006](#bib23){ref-type="other"}). However, excluding cases with phospho-EGFR Tyr-1173 but lacking EGFR staining resulted in a strong correlation between these two markers in our patient subset. We also examined whether the activation status of EGFR could alter the prognostic effect of EGFR. We found that tumours co-expressing phospho-EGFR and EGFR had a similar clinical outcome as those expressing EGFR alone. Therefore, our finding that EGFR, but not phospho-EGFR, is prognostic, suggests that the adverse effect on outcome is not mediated by EGFR activation at Tyr-1173, but by its cross-talk with other pathways.

Anti-EGFR therapies have been shown to inhibit EGFR phosphorylation and to reduce proliferation in human colon cancer cells and in tumour xenografts ([Matar *et al*, 2004](#bib28){ref-type="other"}). Cell lines with ligand-induced EGFR phosphorylation, regardless of EGFR expression levels, show enhanced sensitivity to EGFR inhibitors ([Lynch *et al*, 2004](#bib27){ref-type="other"}; [Paez *et al*, 2004](#bib35){ref-type="other"}). Although IHC analysis of EGFR in colon cancers does not predict the efficacy of anti-EGFR antibody therapy ([Ciardiello and Tortora, 2003](#bib11){ref-type="other"}; [Chung *et al*, 2005](#bib10){ref-type="other"}; [Van Cutsem *et al*, 2007](#bib51){ref-type="other"}), the potential predictive impact of phospho-EGFR expression for anti-EGFR antibodies in human colorectal cancers remains unknown. Given that the majority of patients in our adjuvant studies received 5-fluorouracil-based therapy, we were unable to address its predictive effect. In a limited number of metastatic colorectal carcinomas refractory to irinotecan, higher levels of phospho-EGFR expression were associated with better disease control in patients treated with cetuximab with or without irinotecan ([Personeni *et al*, 2005](#bib37){ref-type="other"}). Furthermore, modulation of phospho-EGFR levels in skin biopsies during anti-EGFR therapy were shown to predict efficacy and may therefore, represent a potential surrogate biomarker ([Agulnik *et al*, 2007](#bib2){ref-type="other"}). Such issues are highly relevant to locoregionally advanced colon cancers, as anti-EGFR antibodies are currently being studied in the adjuvant setting in this patient population.

In conclusion, phospho-EGFR expression was detected in 40% of stage II and III colon carcinomas. Both phospho-EGFR and EGFR overexpression were associated with tumour cell hyperproliferation; however, only EGFR was associated with adverse clinical outcome, thus suggesting that mechanisms other than EGFR activation may underlie its prognostic effect. These data are the first to analyze the prognostic effect of phospho-EGFR in human colon cancer patients, yet further study to examine its predictive utility for anti-EGFR therapy is warranted.

This work was supported in part by a grant from the National Cancer Institute (CA 104683 to FAS).

![Immunohistochemical analysis of phospho-epidermal growth factor receptor (EGFR), EGFR, Ki-67, and caspase-3. (**A**) Colon carcinoma shows phospho-EGFR staining in cytoplasm of tumour cells. Magnification: × 10. (**B**) Colon carcinoma shows membranous EGFR staining intensity (2+). Magnification: × 10. (**C**) Dual staining for caspase-3 (*red*) and Ki-67 (*brown*) allows apoptotic cells to be analysed in context of proliferating cells. Magnification: × 20. The color reproduction of this figure is available on the html full version of the manuscript.](6605473f1){#fig1}

![Univariate analysis of phospho-epidermal growth factor receptor (EGFR) staining intensity and (**A**) disease-free survival (DFS) for p-EGFR positive *vs* negative and (**B**) overall survival (OS) rates for p-EGFR positive *vs* negative in stage II and III colon carcinomas (*n*=388) from patients treated in adjuvant therapy trials.](6605473f2){#fig2}

![Univariate analysis of continuous epidermal growth factor receptor (EGFR) staining intensity showing all the four categories and continuous EGFR *P*-value for (**A**) disease-free (DFS) and (**B**) overall survival (OS) rates in patients with stage II and III colon carcinomas (*n*=361) treated in adjuvant therapy trials. The prognostic effect of EGFR intensity analysed as a dichotomised variable is also shown for (**C**) DFS and (**D**) OS in these patients (*n*=361).](6605473f3){#fig3}

###### 

Univariate survival analysis for p-EGFR and EGFR staining intensity

  **Parameter**                       **Number of patients**   **5-yr DFS %**   **HR (95% CI)**     ***P*-value^a^**   **5-yr OS %**   **HR (95% CI)**     ***P*-value^a^**
  ----------------------------------- ------------------------ ---------------- ------------------- ------------------ --------------- ------------------- ------------------
  *Age (years)*                                                                                                                                            
   ⩽65                                216 (56%)                65.6             ---                 0.40               72.2            ---                 0.18
   \>65                               172 (44%)                59.1             1.15 (0.83, 1.60)                      68.6            1.24 (0.90, 1.72)    
                                                                                                                                                            
  *Gender*                                                                                                                                                 
   Female                             185 (48%)                64.9             ---                 0.37               71.4            ---                 0.72
   Male                               203 (52%)                60.7             1.17 (0.84, 1.62)                      69.9            1.06 (0.77, 1.46)    
                                                                                                                                                            
  *Tumour site*                                                                                                                                            
   Distal                             190 (49%)                61.9             ---                 0.60               71.1            ---                 0.78
   Proximal                           198 (51%)                63.5             0.92 (0.66, 1.27)                      70.2            0.96 (0.69, 1.32)    
                                                                                                                                                            
  *Histological grade*                                                                                                                                     
   Well/moderate                      253 (65%)                65.1             ---                 0.10               74.3            ---                 0.038
   Poor/undifferentiated              135 (35%)                58.3             1.32 (0.95, 1.85)                      63.7            1.41 (1.02, 1.96)    
                                                                                                                                                            
  *Number of lymph nodes*                                                                                                                                  
   0                                  77 (21%)                 80.5             ---                 \< 0.0001          87.0            ---                 \< 0.0001
   1--3                               128 (35%)                66.7             1.78 (0.98, 3.24)                      75.7            1.70 (0.95, 3.04)    
   \>3                                158 (44%)                51.9             3.64 (2.05, 6.44)                      60.1            3.70 (2.12, 6.46)    
                                                                                                                                                            
  *Tumour stage*                                                                                                                                           
   Stage II                           77 (20%)                 80.5             ---                 0.0008             87.0            ---                 0.0008
   Stage III                          311 (80%)                58.3             2.43 (1.42, 4.15)                      66.5            2.38 (1.41, 4.00)    
                                                                                                                                                            
  *MMR status*                                                                                                                                             
   Intact MMR                         327 (91%)                66.1             ---                 0.21               71.4            ---                 0.68
   Defective MMR                      33 (9%)                  78.6             0.62 (0.29, 1.33)                      84.6            0.88 (0.46, 1.67)    
                                                                                                                                                            
  *p-EGFR intensity*                                                                                                                                       
   Absent (0)                         231 (60%)                63.5                                                    71.0                                 
   Weak (1+)                          133 (34%)                63.0             1.01 (0.77, 1.32)   0.95               68.4            1.08 (0.83, 1.40)   0.55
   Moderate (2+)                      24 (6%)                  54.2                                                    79.2                                 
                                                                                                                                                            
  *p-EGFR intensity*                                                                                                                                       
   Absent (0)                         231 (60%)                63.5             ---                 0.99               71.0            ---                 0.60
   Present (1+, 2+)                   157 (40%)                61.6             1.0 (0. 71, 1.40)                      70.1            1.09 (0.78, 1.53)    
                                                                                                                                                            
  *EGFR intensity*                                                                                                                                         
   Absent (0)                         147 (41%)                73.3                                                    78.0                                 
   Weak (1+)                          30 (8%)                  66.7             1.21 (1.03, 1.41)   0.019              73.3            1.19 (1.02, 1.39)   0.028
   Moderate (2+)                      124 (34%)                66.5                                                    72.4                                 
   Strong (3+)                        60 (17%)                 54.7                                                    59.7                                 
                                                                                                                                                            
  *EGFR intensity*                                                                                                                                         
   Absent/weak/moderate (0, 1+, 2+)   301 (83%)                69.8             ---                 0.022              75.2            ---                 0.047
   Strong (3+)                        60 (17%)                 54.7             1.65 (1.07, 2.53)                      59.7            1.55 (1.00, 2.39)    

Abbreviations: CI, confidence interval; DFS, disease-free survival; EGFR, epidermal growth factor receptor; HR, hazard ratio; MMR, mismatch repair; OS, overall survival.

Score *P*-value stratified by adjuvant study.

###### 

Association of EGFR^a^ and phospho-EGFR expression with clinicopathologic variables

                              **Phospho-EGFR intensity (*N*=388)**   **EGFR intensity (*N*=361)**                                                      
  --------------------------- -------------------------------------- ------------------------------ ------------ ------------------ ------------------ -----------
  *Age (years)*                                                                                                                                        
   ⩽65                        123 (53%)                              93 (59%)                       0.24         179 (60%)          29 (48%)           0.11
   \>65                       108 (47%)                              64 (41%)                                    122 (40%)          31 (52%)            
                                                                                                                                                        
  *Gender*                                                                                                                                             
   Female                     107 (46%)                              78 (50%)                       0.52         142 (47%)          31 (52%)           0.52
   Male                       124 (54%)                              79 (50%)                                    159 (53%)          29 (48%)            
                                                                                                                                                        
  *Tumour site*                                                                                                                                        
   Proximal                   111 (48%)                              87 (55%)                       0.15         134 (45%)          33 (55%)           0.14
   Distal                     120 (52%)                              70 (45%)                                    167 (55%)          27 (45%)            
                                                                                                                                                        
  *Histological grade*^c^                                                                                                                              
   1, 2                       146 (63%)                              107 (68%)                      0.32         217 (72%)          37 (62%)           0.11
   3, 4                       85 (37%)                               50 (32%)                                    84 (28%)           23 (38%)            
                                                                                                                                                        
  *Lymph nodes*                                                                                                                                        
   0                          41 (18%)                               36 (26%)                       0.14         80 (27%)           8 (13%)            0.09
   1--3                       86 (38%)                               42 (30%)                                    142 (47%)          32 (53%)            
   \>3                        98 (44%)                               60 (44%)                                    79 (26%)           20 (33%)            
                                                                                                                                                        
  *TNM*                                                                                                                                                
   II                         41 (18%)                               36 (23%)                       0.21         80 (27%)           8 (13%)            0.03
   III                        190 (82%)                              121 (77%)                                   221 (73%)          52 (87%)            
                                                                                                                                                        
  *MMR status*                                                                                                                                         
   Intact MMR                 189 (91%)                              116 (88%)                      0.38         273 (91%)          54 (90%)           0.81
   Defective MMR              19 (9%)                                16 (12%)                                    27 (9%)            6 (10%)             
                                                                                                                                                        
  *Ki-67*                                                                                                                                              
   Median (range)             15.7 (0.0--82.0)                       26.2 (0.6--89.2)               0.015^d,e^   19.6 (0.0--89.2)   42.3 (1.7--85.8)   0.0002^d^
   Mean (s.d.)                24.3 (21.7)                            31.4 (22.8)                                 25.6 (21.9)        39.0 (24.9)         
                                                                                                                                                        
  *Caspase-3*                                                                                                                                          
   Median (range)             0.0 (0.0--20.0)                        0.0 (0.0--46.0)                0.24^d,e^    0.0 (0.0--35.0)    1.5 (0.0--46.0)    0.13^d^
   Mean (s.d.)                2.1 (3.6)                              3.9 (7.8)                                   2.7 (5.1)          3.9 (7.4)           
                                                                                                                                                        
  *Caspase-3 : Ki-67 ratio*                                                                                                                            
   Median (range)             0.0 (0.0--0.4)                         0.0 (0.0--0.4)                 0.54^d,f^    0.0 (0.0--1.4)     0.0 (0.0--0.3)     0.31^d^
   Mean (s.d.)                0.0 (0.1)                              0.0 (0.1)                                   0.0 (0.1)          0.0 (0.1)           

Abbreviations: EGFR, epidermal growth factor receptor; MMR, mismatch repair.

Data are for membranous EGFR staining.

Chi-square *P*-value.

1, 2 (well/moderate); 3, 4 (poor/undifferentiated).

Wilcoxon\'s rank-sum *P*-value.

190 cases with p-EGFR and Ki67, caspase-3.

189 cases with p-EGFR and caspase-3 : Ki67 ratio.

###### 

Multivariate analysis of EGFR intensity as a continuous variable

  **Variable**                                                  **Hazard ratio (95% CI)**   ***P*-value^a^**
  ------------------------------------------------------------- --------------------------- ------------------
  *Multivariate analysis for disease-free survival (N*=*360)*                               
   EGFR intensity (1 U increase)                                1.18 (1.01, 1.38)           0.0415
   Stage (III *vs* II)                                          1.99 (1.20, 3.30)           0.0040
   Histological grade (3/4 *vs* 1/2)                            1.44 (0.98, 2.13)           0.0683
   Age (years) (\> 65 *vs* ⩽65)                                 0.86 (0.59, 1.25)           0.4325
   MMR status (defective *vs* intact)                           0.53 (0.24, 1.15)           0.0771
                                                                                             
  *Multivariate analysis for overall survival (N*=*360)*                                    
   EGFR intensity (1 U increase)                                1.15 (0.98, 1.34)           0.0862
   Stage (III *vs* II)                                          2.19 (1.31, 3.67)           0.0012
   Histological grade (3/4 *vs* 1/2)                            1.62 (1.11, 2.36)           0.0152
   Age (years) (\>65 *vs* ⩽65)                                  0.98 (0.68, 1.41)           0.9043
   MMR status (defective *vs* intact)                           0.69 (0.36, 1.34)           0.2540

Abbreviations: CI, confidence interval; EGFR, epidermal growth factor receptor; MMR, mismatch repair.

Likelihood ratio *P*-value.
